• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Veradigm Inc.

    7/29/24 6:03:59 AM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email
    8-K
    NONE false 0001124804 0001124804 2024-07-26 2024-07-26

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 26, 2024

     

     

    VERADIGM INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-35547   36-4392754
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)
    222 Merchandise Mart    
    Chicago, Illinois     60654
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 800 334-8534

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange on
    which registered

    Common Stock, par value $0.01 per share   MDRX   N/A (OTC Expert Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01.

    Entry into a Material Definitive Agreement.

    On July 26, 2024, Veradigm Inc. (the “Company”) entered into a Stockholder Agreement (the “Stockholder Agreement”) with Charles Myers (“Myers”) and Jessica Myers (together with Myers, the “Myers Parties”).

    Subject to the terms of the Stockholder Agreement, Myers shall serve as a board observer, with the right to attend all meetings of the Company’s board of directors (the “Board”) and Board committees held prior to the Termination Date (as defined below) and receive copies of all documents and other materials provided to the Board in connection with such meetings, in each case, with certain exceptions including if such attendance or receipt of such documents or other materials would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or create or relate to a conflict of interest involving either of the Myers Parties. In addition, the Stockholder Agreement provides that if, prior to the Termination Date, the Board determines to appoint any additional directors, the Board will consider Myers as a candidate for the Board.

    Under the Stockholder Agreement, until the Termination Date, the Myers Parties are subject to certain standstill restrictions, including prohibitions on, directly or indirectly:

     

      •  

    soliciting proxies from the Company’s stockholders;

     

      •  

    making stockholder proposals or Board changes;

     

      •  

    acting alone or in concert with others to seek to control or influence the management, strategies, governance or policies of the Company;

     

      •  

    forming any “group” under Section 13 under the Securities Exchange Act of 1934, as amended, with respect to any shares of Company common stock or otherwise supporting, encouraging or participating in any effort by a third party with respect to the matters set forth above;

     

      •  

    making any books and records demand against the Company; or

     

      •  

    making public statements or any private statements to any third party with respect to (a) any of the foregoing, (b) any extraordinary transaction involving the Company (other than statements with respect to any such transaction publicly announced by the Company in accordance with the Board’s recommendation or with respect to how the Myers Parties intend to vote their shares of Company common stock with respect to such transaction), (c) publicly proposing or privately proposing to any third party any extraordinary transaction involving the Company or (d) any intent, purpose, plan or proposal with respect to the Company or any of the Company’s securities.

    Notwithstanding the foregoing, if the Company holds or schedules an annual meeting of stockholders for which the deadline for nomination notices occurs on or prior to the Termination Date, Myers may submit a nomination notice with respect to himself. If he submits such a nomination notice, notifies the Board or the Secretary of his intention to submit such a nomination notice or fails to confirm that he has no intention to submit such a nomination notice within a specified time period following a request from the Company, Myers’s right to serve as a board observer will terminate, and, beginning at the time specified in the Stockholder Agreement, he may make public or private statements or otherwise solicit proxies in support of his election as a director.

     


    Until the Termination Date, each party to the Stockholder Agreement has (a) committed not to make any public statement or private statement to a third party that criticizes or disparages the other party, its subsidiaries, its business or its current or former directors, officers or employees (in each case, in their capacity as such), subject to certain customary exceptions, and (b) undertaken not to sue the other party except to remedy a breach of the Stockholder Agreement or the Confidentiality Agreement (as defined below).

    The Stockholder Agreement will terminate on the earliest of (a) the date on which a change of control of the Company is consummated, (b) the later of (i) January 26, 2025 and (ii) the date on which the Company becomes current in its U.S. Securities Exchange Commission financial reporting obligations and (c) July 26, 2025 (such earliest date, the “Termination Date”). Additionally, certain obligations will terminate in customary circumstances involving a breach of the Stockholder Agreement or the Confidentiality Agreement. Further, Myers’s right to serve as a board observer will terminate if the Myers Parties on any date cease to beneficially own at least 3,000,000 shares of Company common stock (subject to adjustment for stock splits, reclassifications, combinations and similar adjustments).

    Concurrently with the execution of the Stockholder Agreement, Myers and the Company also entered into a confidentiality agreement (the “Confidentiality Agreement”) with customary obligations to keep information furnished to Myers by or on behalf of the Company, its affiliates or representatives or obtained by Myers through discussions with employees, board members or other representatives of the Company or its affiliates strictly confidential from the date of the Stockholder Agreement through the second anniversary of the date on which Myers ceases to be a board observer, subject to customary exceptions. Pursuant to the terms of the Confidentiality Agreement, Myers has agreed not to use any Confidential Information (as defined in the Confidentiality Agreement) other than for purposes of serving as a board observer and for evaluating his investment in the Company.

    The foregoing description of the Stockholder Agreement is qualified in its entirety by reference to the full text thereof, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 9.01.

    Financial Statements and Exhibits.

     

    (d)

    Exhibits:

     

    Exhibit
    No.

      

    Description

    10.1+    Stockholder Agreement, dated as of July 26, 2024, by and among Veradigm Inc., Charles Myers and Jessica Myers
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    +

    Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        VERADIGM INC.
    Date: July 29, 2024     By:  

    /s/ Eric Jacobson

        Name:   Eric Jacobson
        Title:   Senior Vice President, Deputy General Counsel and Corporate Secretary
    Get the next $MDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradigm Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan to December 31, 2026 (the "Rights Plan"). The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Rights Plan will continue to be present beyond February 20, 2026. Accordingly, the Rights Plan is being extended to continue to ensure that all Veradigm stockholders have the opportunity to realize the full potential value of their in

    2/2/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent Practices

    New AI-driven application helps Revenue Cycle Services clients gain faster, clearer visibility into financial performance Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving rev

    1/28/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain Integrity

    A next-generation, hospital-first EDI platform delivering transparency, accuracy, and data governance to healthcare supply chains Veradigm® (OTC:MDRX), a leading provider of healthcare data, technology, and enterprise resource planning (ERP) solutions, and Meperia (now part of Genesis Automation Healthcare), a healthcare supply chain technology company specializing in AI-powered content and spend management solutions, announced today a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industr

    1/15/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veradigm downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

    3/19/24 7:50:39 AM ET
    $MDRX
    EDP Services
    Technology

    Barclays initiated coverage on Veradigm with a new price target

    Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

    1/3/24 8:00:02 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm downgraded by Argus

    Argus downgraded Veradigm from Buy to Hold

    7/6/23 9:00:49 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief HR Officer Hammond Lisa was granted 58,140 shares, increasing direct ownership by 50% to 174,175 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:28:24 PM ET
    $MDRX
    EDP Services
    Technology

    SVP General Counsel Vakharia Tejal was granted 69,768 shares, increasing direct ownership by 22% to 387,476 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:22:40 PM ET
    $MDRX
    EDP Services
    Technology

    Director Sacks Jonathan S was granted 46,512 shares and converted options into 8,696 shares (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/3/25 9:28:21 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    SEC Filings

    View All

    Amendment: SEC Form 8-A12G/A filed by Veradigm Inc.

    8-A12G/A - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:47:45 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:23:23 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Veradigm Inc. (0001124804) (Filer)

    1/20/26 4:10:24 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

    4/A - Veradigm Inc. (0001124804) (Issuer)

    3/15/24 5:16:45 PM ET
    $MDRX
    EDP Services
    Technology

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    3/4/24 9:50:46 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/8/24 10:29:29 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    $MDRX
    Financials

    Live finance-specific insights

    View All

    Veradigm Amends and Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene

    8/20/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm to Release Business Update June 23rd and Host Investor Call June 24th

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan

    6/18/25 5:27:00 PM ET
    $MDRX
    EDP Services
    Technology

    STAAR Surgical Announces Changes to Board of Directors

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

    4/24/25 5:00:00 PM ET
    $AZN
    $CRVL
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Insurers
    Finance